Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today ...
Stocktwits on MSN
VKTX vs. GPCR: Which obesity drug developer does Wall Street see with the bigger upside?
Earlier this month, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. ・Structure ...
Valuation and recent performance snapshot Structure Therapeutics (GPCR) has drawn attention after recent trading moves, ...
Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a ...
G-protein-coupled receptors’ star has been on the rise in biotech in recent years as researchers have discovered the vast potential for GPCR-targeting drugs in treating a range of health conditions, ...
Nuclera’s nanodisc panel includes a GPCR screen kit and scale-up reagents, including 8 nanodisc combinations, comprised of 2 ...
Novo Nordisk faces slowing growth and rising competition, while Structure Therapeutics shows strong obesity study results, ...
CHICAGO--(BUSINESS WIRE)--Exicure, Inc. (Nasdaq: XCUR, “Exicure”, “the Company”), has announced the signing of a Memorandum of Understanding (MOU) with GPCR ...
Investors in Structure Therapeutics Inc (Symbol: GPCR) saw new options begin trading today, for the December 2026 expiration. One of the key data points that goes into the price an option buyer is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results